三陰乳腺癌PD-L1（SP142）與CTLA-4、PTEN表達的關係研究

A study on relationship between the expression of PD-L1(SP142), CTLA-4 and PTEN in triple-negative breast cancer

10.12408/J.issn2223-4462.2024.01.006

韋潔貞(WAI Kit Cheng)；林文華(LAM Man Wa)；冼麗芳(SIN Lai Fong)；陳建勇(CHAN Kin Iong)；黃香婷(WONG Heong Ting)；肖剛(XIAO gang)；文劍明(WENJian Ming)

三陰乳腺癌 ； PD-L1（SP142） ； CTLA-4 ； PTEN ； Triple-negative breast cancer ； PD-L1(SP142) ； CTLA-4 ； PTEN

鏡湖醫學

24卷1期（2024 / 06 / 01）

20 - 23+i

繁體中文;英文

目的：探討三陰乳腺癌PD-L1（SP142）與CTLA-4、PTEN表達的關係和意義。方法：收集鏡湖醫院2008年1月～2018年6月間病理科136例乳腺癌標本，按乳腺癌分子分型分為三陰乳腺癌（TNBC）、管腔A型、管腔B型及HER2型乳腺癌，採用免疫組化檢測各型乳腺癌PD-L1（SP142）、CTLA-4和PTEN表達情況，並分析它們之間的關係。結果：136例乳腺癌中，32.4%的病例PD-L1（SP142）陽性，其中48%（24/50）TNBC、11.9%（5/42）管腔A型、20%（3/15）管腔B型和41.4%（12/29）HER2型PD-L1（SP142）陽性；43.4%的病例CTLA-4陽性，其中52.0%（26/50）TNBC、31.0%（13/42）管腔A型、33.3%（5/15）管腔B型和50.9%（15/29）HER2型CTLA-4陽性；28.0%的病例PTEN陽性，其中52.0%（26/50）TNBC、31.0%（13/42）管腔A型、33.3%（5/15）管腔B型和50.9%（15/29）HER2型PTEN陽性。TNBC的PD-L1（SP142）表達與CTLA-4表達呈正相關（Spearman=0.409, P<0.05），與PTEN表達呈負相關（Spearman=-0.318, P<0.05）。結論：TNBCPD-L1（SP142）與CTLA-4表達的正相關關係，提示聯合免疫治療可能使TNBC患者獲益，而TNBCPD-L1（SP142）與PTEN表達的負相關關係，提示TNBC同時遭受免疫逃逸和基因突變的雙重打擊，因此適合免疫治療和靶向PTEN聯合治療。

Objective: To explore the relationship between PD-L1(SP142) and CTLA-4, PTEN expression in triple-negative breast cancer (TNBC). Methods: One hundred and thirty six cases of breast cancer were collected in Kiang Wu Hospital of Macau from January 2008 to June 2018, and divided into 4 groups according to molecular classification,including TNBC, Luminal A, Luminal B and HER2-enriched. Expressions of PD-L1(SP142), CTLA-4 and PTEN were detected by immunohistochemical staining in the breast cancers. The relationship between PD-L1(SP142) expression and CTLA-4, PTEN expression were analyzed in TNBC and other molecular types of breast cancer. Results: Among the 136 cases of breast cancer, 32.4% of cases were PD-L1(SP142) positive, in which, 48% (24/50) TNBC, 11.9% (5/42) Luminal A , 20% (3/15) Luminal B and 41.4% (12/29) HER2-enriched were PD-L1(SP142) positive. Among the 136 cases of breast cancer, 43.4% of cases were CTLA-4 positive, in which, 52.0% (26/50) TNBC, 31.0% (13/42) Luminal A, 33.3% (5/15) Luminal B and 50.9% (15/29) HER2-enriched were CTLA-4 positive. Among the 136 cases of breast cancer, 28.0% of cases were PTEN positive, in which, 52.0% (26/50) TNBC, 31.0% (13/42) Luminal A , 33.3% (5/15) Luminal B and 50.9% (15/29) HER2-enriched were PTEN positive. The expression of PD-L1( SP142) was positively correlated with the expression of CTLA-4in TNBC (Spearman=0.409, P<0.05), but negatively correlated with the expression of PTEN (Spearman=-0.318, P<0.05). Conclusion: The positively correlation betweenPD-L1(SP142)and CTLA-4 in TNBC suggests that combined immunotherapy may benefit TNBC patients, the negative correlation between PD-L1(SP142) andPTEN suggests that TNBC may suffer from double hits(immune escape and gene mutation), so TNBC is suitable for combining immunotherapy and targeted PTEN therapy.